The rat neu oncogene encodes a constitutively activated growth factor receptor/transmembrane tyrosine kinase, pl85Tneu, that is structurally similar to yet distinct from the epidermal growth factor receptor. To explore the role of the carboxyl-terminal region and of putative autophosphorylation sites in regulating the activity of the rat pl85Tneu (T, transforming) protein, we used site-directed mutagenesis to generate a pl85Tneu mutant in which a putative tyrosine autophosphorylation site (residue 1253) at the extreme carboxyl terminus was replaced by a phenylalanine residue and a mutant in which the carboxyl-terminal 122 amino acids were deleted. These proteins were expressed in NIH 3T3 cells at comparable levels and exhibited similar autophosphorylation activity, exogenous substrate phosphorylation ability, oligomerization levels, and responsiveness to a partially purified neu-activating factor. However, the mutant pl85Tneu proteins displayed a decreased transforming capacity both in vitro and in vivo. This analysis demonstrated that the carboxyl-terminal domain and at least one putative tyrosine autophosphorylation site of pl85Tneu play a role in positively regulating the cell growth-regulating properties of the neu protein.
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Transmembrane tyrosine kinases such as the neu protein, its human homologue the c-erbB-2 protein, and the closely related epidermal growth factor receptor (EGFR) possess a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane-spanning domain, and a cytoplasmic tyrosine kinase domain (1) . Ligand binding to the extracellular domain results in receptor aggregation, activation of the kinase domain, and phosphorylation of intrinsic substrates (2) . How these signals are ultimately translated into mitogenic and/or differentiation-altering effects is not fully known.
The rat neu oncogene product is termed pl85Tneu (T, transforming) and was originally identified as the transforming protein in chemically induced rat neuroglioblastomas (3, 4) . Constitutive activation of its tyrosine kinase domain was found to confer its potent transforming activity compared with its nontransforming cellular homologue, p185c-neu (5) (6) (7) . The EGFR protein cannot transform cells in the absence of ligand (8) . The oncogenic pl85Tneu protein can, however, completely transform NIH 3T3 cells. Thus, in the absence of cloned, purified ligand for the neu protein, the pl85Tneu protein represents a system in which elevated kinase activity and transforming ability (both reminiscent of ligand-induced activation) are already present.
Though EGFR and the neu/c-erbB-2 gene product share extensive structural and sequence homology, these proteins are only 30% homologous in their carboxyl-terminal region (9, 10) . Their dissimilar carboxyl-terminal domains, which contain autophosphorylation and substrate association sites, most likely contribute to the apparent differential regulation of these closely related transmembrane tyrosine kinases (11, 12) . The role of the carboxyl-terminal region and of the autophosphorylation sites contained within this region have been explored as they relate to EGFR and c-erbB-2 regulation but have not been examined extensively for rat neu protein regulation.
To explore the role of the carboxyl-terminal region and of putative autophosphorylation sites in the regulation of the rat neu protein, we have generated mutants of the carboxylterminal region of pl85Tneu. The constructs encoding these mutants were transfected into NIH 3T3 mouse fibroblasts for subsequent phenotypic characterization. Studies of these mutant proteins and of the wild-type p185Tneu protein in the same cellular backround at comparable expression levels permitted the investigation of the role of the carboxylterminal region and of putative autophosphorylation sites in neu protein regulation.
MATERIALS AND METHODS
Construction of Mutants. Plasmid pSV2neuT contains a cDNA that encodes rat pl85Tneu (9) . A 2.7-kilobase DNA fragment (from pSV2neuT) spanning the carboxyl-terminal region of the p185Tneu protein was subcloned into the plasmid pGEM-5Zf (Promega). Single-stranded uridylated DNA template was generated (13) . In vitro oligonucleotidedirected mutagenesis was performed (14) and the mutations were verified by DNA sequencing (15 tTo whom reprint requests should be addressed.
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3T3/Tneu, NIH 3T3/T/1253F, and NIH 3T3/T/APstop cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum under an atmosphere of 5% CO2 at 37C and were passaged every 3-4 days.
Western Blotting. Immunoprecipitation and Western blotting were performed as described (17, 18 
RESULTS
Characterization of pl85Tneu and Mutants. The structural organization of the native and mutant pl85Tneu proteins is depicted in Fig. 1 (19)], or the anti-phosphotyrosine antibody PY-20 ( Fig. 2A) . All three proteins were expressed at similar levels, were recognized by anti-Bacneu, and possessed comparable levels of phosphotyrosine. The pl85T/APstop protein was not recognized by DBW-2, because this antiserum was specific for carboxyl-terminal residues that have been deleted in the p185T/APstop mutant. These experiments indicated that the different forms of pl85Tneu were expressed at similar levels and were appropriately processed and localized to the cell surface. Thus any differences between the cell lines can be attributed to the introduced mutations in the pl85Tneu protein.
Dimerization/Oligomerization. Oncogenic pl85Tneu exists in both monomeric and homodimeric forms. To assess the aggregation state of the pl85Tneu proteins, covalent crosslinking studies were performed with the lipid-impermeant covalent crosslinking reagent BS3. The crosslinked products (Fig. 2B ) from each cell line had molecular weights comparable to that of pl85Tneu homodimer from B104-1-1 cells (22) . Anti-phosphotyrosine Western blots revealed that phosphotyrosine density was nearly equally distributed between the monomeric and dimeric forms of each pl8STneu species (Fig.   2B ).
In Vitro Autophosphorylation and Phosphorylation of Exogenous Substrate. The basal kinase activity of the mutant pl85Tneu proteins was first assessed. Since the autophosphorylation and substrate phosphorylation capabilities of the constitutively activated pl85Tneu protein are higher than those of the p185c-neu, we included a cell line that expresses p185c-neu as a control and for comparison. As expected, basal kinase activity levels of native and both mutant pl85Tneu proteins were higher than that of the p185c-neu protein (Fig. 3) . Both mutant pl85Tneu proteins displayed comparable basal autophosphorylation levels and exogenous substrate (histone H3) phosphorylation levels when compared with the native pl85Tneu expressed in the same cellular background (Fig. 3) .
Responsiveness to NAF was also examined. NAF interacts with the extracellular domain of the p185c-neu protein, resulting in neu protein kinase activation, dimerization, internalization, and growth potentiation (20) . NAF-dependent enhancement ofautophosphorylation and phosphorylation of the exogenous substrate histone H3 was found to be comparable for both mutants and for the wild-type pl85Tneu protein (Fig. 3) .
NAF-Dependent Internaliation. To further assess the functioning of these proteins, we examined their ability to be internalized in response to NAF. Native p185Tneu surface Proc. Natl. Acad. Sci. USA 89 (1992) expression was decreased 10%o at 30 min and 23% at 120 min (Fig. 4) . With the mutants, NAF induced a 16% decrease in p185T/APstop surface expression and a 20%o decrease in p185T/1253F surface expression after 120 min (Fig. 4) , indicating that these proteins responded similarly with regard to ligand-mediated internalization.
In Vitro Transforming Ability. In the in vitro focus formation assay, expression of pl85Tneu in either the NIH 3T3 or the NR6 cell background resulted in large, clear foci against the background of NIH 3T3 cells, whereas the p185c-neuexpressing cell line (PN-NR6) and untransfected NIH 3T3 cells did not form foci (Fig. 5) . The NIH 3T3/p185T/APstop cell line displayed smaller, less well-defined foci than the NIH 3T3/pl85Tneu cell line. The NIH 3T3/p185T/1253F cell line also displayed decreased focus formation, though the diminution in transforming ability in this assay was less severe than that observed for the NIH 3T3/pl85T/APstop cell line (Fig. 5) .
In Vivo Transforming Ability. The transforming capability of these proteins was further assessed by observing their ability to form progressive tumors in nude mice. Tumor volume at the end of the fourth week following tumor implantation was significantly larger for NIH 3T3/pl85Tneu cells than for NIH 3T3/p185T/APstop cells, whereas the NIH 3T3/p185T/1253F cell line displayed an intermediate phenotype (Fig. 6 ).
DISCUSSION
The oncogenic, deregulated pl85Tneu protein was used to define determinants involved in regulating the transforming ability ofthe activated neu protein. Site-directed mutagenesis was employed to delete or alter regions in the carboxylterminal region thought to be involved in pl85Tneu regula- tion. In the mutant designated pl85T/1253F, a putative autophosphorylation site, tyrosine-1253 of pl85Tneu, was changed to phenylalanine. In the second pl85T/APstop, the carboxyl-terminal 122 amino acids (including three putative tyrosine autophosphorylation sites) were deleted. The mutant proteins displayed comparable autophosphorylation and exogenous substrate phosphorylation activity, receptor aggregation state, and ability to respond to NAF when compared with native pl85Tneu. However, both of the mutants displayed decreased transforming ability in vitro as well as in vivo. The ability of p185T/APstop to induce foci in vitro and tumors in nude mice was impaired and p185T/1253F protein was somewhat impaired. The decreased transforming ability of the pl85Tneu/APstop truncation mutant and the p185T/ 1253F substitution mutant implicates the carboxyl terminus itself and at least one putative tyrosine autophosphorylation site within this region in the positive regulation of the rat neu protein. These studies also indicate distinctions between early (receptor aggregation, internalization, and phosphorylation) and late (focus formation and tumor formation) growth-related effects.
The virally transduced, oncogenic forms ofthe c-erb-B and c-fms transmembrane tyrosine kinases are proteins that lack portions of the carboxyl terminus and possess activated kinase domains and elevated transforming potential compared with their cellular, protooncogenic homologues (1). Deletions of the carboxyl-terminal region of the human EGFR/c-erbB and c-erbB-2 proteins result in a decrease in the transforming capacity of these molecules, demonstrating that this region can also positively regulate function (11, 23, 24) . The role of the carboxyl-terminal region of the neu protein suggested by our studies is consistent with these studies. However, other studies have described contradictory results. One recent study (25) described a carboxylterminally truncated c-erbB-2 mutant that had a 3-fold increase in in vitro focus formation relative to the full-length protein containing the transforming transmembrane point mutation. Another study (26) found no difference in the transforming ability of a rat pl85Tneu mutant that lacked most (-270 amino acids) ofthe carboxyl-terminal region. The differences between these data on the role of the carboxylterminal region in transformation may be due to differences between the human and rat neu protein sequences, to differences in their regulation, or to the different sizes of the deletions used in each study. In addition, some studies examined only one characteristic of the malignant phenotype (i.e., focus formation or growth rate) and did not examine in vivo tumorigenicity.
Autophosphorylation may play a different role in regulating the activity of different tyrosine kinases. Though auto- phosphorylation has been shown to alter the activity of other tyrosine kinases such as the c-src gene product, the insulin receptor, and the c-fms gene product (27) , studies of the consequences of EGFR autophosphorylation have given conflicting results. Some studies have shown that EGFR autophosphorylation increased the activity ofreceptor kinase (28), while others, using comparable assays, have found little change in the enzymatic or biological activity of this protein (29) (30) (31) . The role of autophosphorylation in the regulation of the neu protein or its human homologue, the c-erbB-2 protein, has not been adequately addressed, although some of the potential autophosphorylation sites of the human c-erbB-2 protein have been mapped (32, 33) .
We examined the role of a putative autophosphorylation site of the constitutively activated pl85Tneu protein expressed by a simian virus 40 promoter/expression system and detected a significant, positive role of this autophosphorylation site in transformation. The alteration of the transforming capacity of the neu protein as a result of the site-directed mutagenesis of a single autophosphorylation site (tyrosine-1253) was not fully recognized in previous studies. Human c-erbB-2 autophosphorylation-site mutants did not reveal a role for any individual autophosphorylation site in in vitro transformation assays (24) . This study was complicated by the extremely high levels of c-erbB-2 protein expression driven by a Moloney leukemia virus long terminal repeat promoter. These levels of receptor expression may result in less stringent requirement for the phosphorylation of each individual tyrosine residue for transformation. However, multiple autophosphorylation-site mutations did result in a decrease in the transforming potential of the c-erbB-2 protein (24), which is consistent with our own findings. Another recent study of c-erbB-2 autophosphorylation states revealed a decrease in the transforming ability when tyrosine-1248 was changed to phenylalanine (25) . This finding is similar to ours, since the autophosphorylation-site mutation was introduced into a c-erbB-2 protein that also contained a substitution of valine for glutamate-659, and we introduced our autophosphorylation-site mutation into the rat neu protein, which also possesses this transmembrane-region mutation.
We have presented evidence that the availability of tyrosine-1253 and of other autophosphorylation sites (contained within the 122-amino acid deletion) may be critical in positively regulating some of the growth/transforming abilities of pl85Tneu. In addition, the magnitude of the decrease in transforming potential correlated with the number of tyrosine autophosphorylation sites that were deleted. Therefore, some of the differences in the neu and EGFR signaling potential revealed through studies of receptor chimeras (11) and some of the differences in their signal-coupling efficacy in different cell types (12) could be related to differential consequences of autophosphorylation between these two receptors. Future studies of the role of autophosphorylation and of the carboxyl-terminal region as a whole in neu protein regulation, particularly in the p185c-neu context, will be facilitated by a more complete understanding of the substrate specificities of this protein and by the complete purification and availability of its ligand.
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